[go: up one dir, main page]

WO2016181220A3 - Therapeutic compositions comprising a combination from a curcumin, a harmine and isovanillin component and methods of use thereof - Google Patents

Therapeutic compositions comprising a combination from a curcumin, a harmine and isovanillin component and methods of use thereof Download PDF

Info

Publication number
WO2016181220A3
WO2016181220A3 PCT/IB2016/000723 IB2016000723W WO2016181220A3 WO 2016181220 A3 WO2016181220 A3 WO 2016181220A3 IB 2016000723 W IB2016000723 W IB 2016000723W WO 2016181220 A3 WO2016181220 A3 WO 2016181220A3
Authority
WO
WIPO (PCT)
Prior art keywords
harmine
combination
curcumin
methods
therapeutic compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2016/000723
Other languages
French (fr)
Other versions
WO2016181220A2 (en
Inventor
Gene H. Zaid
Thomas W. BURGOYNE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ions Pharmaceutical Sa Rl
Original Assignee
Ions Pharmaceutical Sa Rl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/721,011 external-priority patent/US9402834B2/en
Priority claimed from PCT/US2015/055968 external-priority patent/WO2016064676A1/en
Application filed by Ions Pharmaceutical Sa Rl filed Critical Ions Pharmaceutical Sa Rl
Priority to US15/337,987 priority Critical patent/US9907786B2/en
Priority to US15/337,795 priority patent/US10092550B2/en
Priority to US15/338,020 priority patent/US20170042867A1/en
Priority to US15/337,957 priority patent/US20170105976A1/en
Priority to US15/337,882 priority patent/US20170105975A1/en
Publication of WO2016181220A2 publication Critical patent/WO2016181220A2/en
Publication of WO2016181220A3 publication Critical patent/WO2016181220A3/en
Priority to US15/486,406 priority patent/US20170216222A1/en
Anticipated expiration legal-status Critical
Priority to US15/826,101 priority patent/US20180078535A1/en
Priority to US16/213,774 priority patent/US10471049B2/en
Priority to US16/541,665 priority patent/US10576067B2/en
Priority to US16/541,626 priority patent/US10532043B2/en
Priority to US16/541,695 priority patent/US10507200B1/en
Priority to US16/724,979 priority patent/US10751330B2/en
Priority to US16/724,935 priority patent/US10744124B2/en
Priority to US17/000,164 priority patent/US11266634B2/en
Priority to US17/589,060 priority patent/US11951099B2/en
Priority to US19/175,484 priority patent/US20250255853A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective., for the treatment of human conditions, especially human cancers.
PCT/IB2016/000723 2014-10-21 2016-04-20 Therapeutic compositions and methods of use thereof Ceased WO2016181220A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
US15/337,987 US9907786B2 (en) 2014-10-21 2016-10-28 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US15/337,795 US10092550B2 (en) 2014-10-21 2016-10-28 Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US15/338,020 US20170042867A1 (en) 2014-10-21 2016-10-28 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US15/337,957 US20170105976A1 (en) 2014-10-21 2016-10-28 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US15/337,882 US20170105975A1 (en) 2014-10-21 2016-10-28 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US15/486,406 US20170216222A1 (en) 2014-10-21 2017-04-13 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US15/826,101 US20180078535A1 (en) 2014-10-21 2017-11-29 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US16/213,774 US10471049B2 (en) 2014-10-21 2018-12-07 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US16/541,695 US10507200B1 (en) 2014-10-21 2019-08-15 Therapeutics compositions containing harmine and isovanillin components, and methods of use thereof
US16/541,665 US10576067B2 (en) 2014-10-21 2019-08-15 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US16/541,626 US10532043B2 (en) 2014-10-21 2019-08-15 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US16/724,935 US10744124B2 (en) 2014-10-21 2019-12-23 Human therapeutic agents
US16/724,979 US10751330B2 (en) 2014-10-21 2019-12-23 Human therapeutic agents
US17/000,164 US11266634B2 (en) 2014-10-21 2020-08-21 Methods for treating melanoma with human therapeutic agents
US17/589,060 US11951099B2 (en) 2014-10-21 2022-01-31 Methods for treating plasma cell neoplasm with human therapeutic agents
US19/175,484 US20250255853A1 (en) 2015-05-13 2025-04-10 Human therapeutic agents

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562161090P 2015-05-13 2015-05-13
US62/161,090 2015-05-13
US14/721,011 US9402834B2 (en) 2014-10-21 2015-05-26 Human therapeutic agents
US14/721,011 2015-05-26
US201562184051P 2015-06-24 2015-06-24
US62/184,051 2015-06-24
USPCT/US2015/055968 2015-10-16
PCT/US2015/055968 WO2016064676A1 (en) 2014-10-21 2015-10-16 Human therapeutic agents

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US14/721,011 Continuation-In-Part US9402834B2 (en) 2014-10-21 2015-05-26 Human therapeutic agents
PCT/US2015/055968 Continuation-In-Part WO2016064676A1 (en) 2014-10-21 2015-10-16 Human therapeutic agents

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US14/721,011 Continuation US9402834B2 (en) 2014-10-21 2015-05-26 Human therapeutic agents
US15/337,987 Continuation US9907786B2 (en) 2014-10-21 2016-10-28 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US15/337,795 Continuation US10092550B2 (en) 2014-10-21 2016-10-28 Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof

Publications (2)

Publication Number Publication Date
WO2016181220A2 WO2016181220A2 (en) 2016-11-17
WO2016181220A3 true WO2016181220A3 (en) 2016-12-29

Family

ID=57248993

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/000723 Ceased WO2016181220A2 (en) 2014-10-21 2016-04-20 Therapeutic compositions and methods of use thereof

Country Status (2)

Country Link
TW (1) TW201713323A (en)
WO (1) WO2016181220A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
JP7646243B2 (en) * 2020-12-17 2025-03-17 ホン，ミェン―チェ Use of the pharmaceutical composition in treating lung cancer
CN114671779B (en) * 2022-03-15 2023-08-22 温州医科大学 Compounds containing cyclopentanone fragments and their application as antitumor drugs

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2869540A1 (en) * 2004-04-30 2005-11-04 Centre Nat Rech Scient PHARMACEUTICAL COMPOSITIONS CONTAINING B-CARBOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER
US20080221221A1 (en) * 2005-08-25 2008-09-11 Pingkun Zhou Application of 2-bromide-isovanillin for the manufacture of a medicament for anti-cancer or/and radiation/chemotherapy sensitization
WO2008150899A1 (en) * 2007-05-29 2008-12-11 Emory University Combination therapies for treatment of cancer and inflammatory diseases
WO2011133795A2 (en) * 2010-04-22 2011-10-27 The Brigham And Women's Hospital, Inc. Beta-carbolines as inhibitors of haspin and dyrk kinases
US20120058208A1 (en) * 2010-09-04 2012-03-08 Synthite Industries Ltd. Synergistic Composition for Enhancing Bioavailability of Curcumin
WO2015006646A1 (en) * 2013-07-11 2015-01-15 Specialty Nutrition Group, Inc. Compositions comprising hydroxytyrosol, curcumin, and/or astaxanthin and use thereof
WO2016064676A1 (en) * 2014-10-21 2016-04-28 Genzada Pharmaceuticals Llc Human therapeutic agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735154B2 (en) 2006-10-30 2014-05-27 The University Of Kansas Templated islet cells and small islet cell clusters for diabetes treatment
US8039025B1 (en) 2010-10-15 2011-10-18 Life Plus, LLC Methods and dosage forms for the treatment of human cancers

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2869540A1 (en) * 2004-04-30 2005-11-04 Centre Nat Rech Scient PHARMACEUTICAL COMPOSITIONS CONTAINING B-CARBOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER
US20080221221A1 (en) * 2005-08-25 2008-09-11 Pingkun Zhou Application of 2-bromide-isovanillin for the manufacture of a medicament for anti-cancer or/and radiation/chemotherapy sensitization
WO2008150899A1 (en) * 2007-05-29 2008-12-11 Emory University Combination therapies for treatment of cancer and inflammatory diseases
WO2011133795A2 (en) * 2010-04-22 2011-10-27 The Brigham And Women's Hospital, Inc. Beta-carbolines as inhibitors of haspin and dyrk kinases
US20120058208A1 (en) * 2010-09-04 2012-03-08 Synthite Industries Ltd. Synergistic Composition for Enhancing Bioavailability of Curcumin
WO2015006646A1 (en) * 2013-07-11 2015-01-15 Specialty Nutrition Group, Inc. Compositions comprising hydroxytyrosol, curcumin, and/or astaxanthin and use thereof
WO2016064676A1 (en) * 2014-10-21 2016-04-28 Genzada Pharmaceuticals Llc Human therapeutic agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANTONIO RESCIGNO ET AL: "Vanilloid Derivatives as Tyrosinase Inhibitors Driven by Virtual Screening-Based QSAR Models", DRUG TESTING AND ANALYSIS, vol. 3, no. 3, 1 December 2010 (2010-12-01), GB, pages 176 - 181, XP055297241, ISSN: 1942-7603, DOI: 10.1002/dta.187 *
PANAGIOTA A. SOTIROPOULOU ET AL: "Chemical approaches to targeting drug resistance in cancer stem cells", DRUG DISCOVERY TODAY., vol. 19, no. 10, 1 October 2014 (2014-10-01), US, pages 1547 - 1562, XP055297181, ISSN: 1359-6446, DOI: 10.1016/j.drudis.2014.05.002 *
S. DURANT: "Vanillins--a novel family of DNA-PK inhibitors", NUCLEIC ACIDS RESEARCH, vol. 31, no. 19, 1 October 2003 (2003-10-01), pages 5501 - 5512, XP055318556, DOI: 10.1093/nar/gkg753 *
Y. ZHANG ET AL: "Identification of Inhibitors of ABCG2 by a Bioluminescence Imaging-Based High-Throughput Assay", CANCER RESEARCH, vol. 69, no. 14, 30 June 2009 (2009-06-30), pages 5867 - 5875, XP055076421, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-08-4866 *

Also Published As

Publication number Publication date
WO2016181220A2 (en) 2016-11-17
TW201713323A (en) 2017-04-16

Similar Documents

Publication Publication Date Title
CA2956871C (en) Compounds active towards bromodomains
MX2017002489A (en) Human therapeutic agents.
WO2017095944A8 (en) Methods and compositions relating to chondrisomes from blood products
EP3481402A4 (en) Compounds, compositions, and methods for the treatment of disease
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
EP3675859A4 (en) Compounds, compositions, and methods for the treatment of disease
EP3686200A3 (en) Bicyclic heterocycle compounds and their uses in therapy
IL258854A (en) Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
EP3484504A4 (en) Compounds, compositions, and methods for the treatment of disease
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
EP3481323A4 (en) Cardiac arrhythmia treatment devices and delivery
EP3268007A4 (en) Compositions and therapeutic methods for the treatment of complement-associated diseases
WO2016181220A3 (en) Therapeutic compositions comprising a combination from a curcumin, a harmine and isovanillin component and methods of use thereof
USD828568S1 (en) Ultrasound and electrotherapy device
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
EP3337482A4 (en) Transdermal formulations for delivery of berberine compounds, and their use in the treatment of berberine-responsive diseases and conditions
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
WO2017120527A3 (en) Therapeutic compositions and methods for treating hepatitis b
WO2016130581A8 (en) Combination cancer therapy
WO2017079403A3 (en) Polymeric nanoparticles
HK1254231A1 (en) Mito-honokiol compounds and methods of synthesis and use thereof
EP3677267A4 (en) Pharmaceutical composition for tumor treatment or prevention, method, and use thereof
IL249860A0 (en) Pharmaceutical compositions, methods for their preparation and their use in the treatment of cancer
WO2017117386A8 (en) Methods of treating cancer using network brakes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16731962

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16731962

Country of ref document: EP

Kind code of ref document: A2